scispace - formally typeset
J

John L. Decker

Researcher at National Institutes of Health

Publications -  95
Citations -  10797

John L. Decker is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Lupus erythematosus & Arthritis. The author has an hindex of 46, co-authored 95 publications receiving 10540 citations.

Papers
More filters
Journal ArticleDOI

Preliminary criteria for the classification of the acute arthritis of primary gout

TL;DR: The American Rheumatism Association sub-committe on classification criteria for gout analyzed data from more than 700 patients with gout, pseudogout, rheumatoid arthritis, or septic arthritis to establish criteria for classifying a patient as having gout.
Journal ArticleDOI

Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.

TL;DR: It is concluded that, as compared with high-dose oral prednisone alone, treatment of lupus glomerulonephritis with intravenous cyclophosphamide reduces the risk of end-stage renal failure with few serious complications.
Journal ArticleDOI

Increased Risk of Lymphoma in Sicca Syndrome

TL;DR: Patients with a history of parotid enlargement, splenomegaly, and lymphadenopahy had an increased risk of lymphoma and clinical conditions did not appear to be early manifestations of undiagnosed lymphoma but rather seemed to identify a subgroup of patients with sicca syndrome with marked lymphoid reactivity, who had a particularly high risk of subsequently developing lymphoma.
Journal ArticleDOI

Immune interferon in the circulation of patients with autoimmune disease.

TL;DR: It is possible that the production of interferon may contribute to immunologic aberrations in auto-immune diseases and also protect the already compromised host from viral infections.
Journal ArticleDOI

Prognostic factors in lupus nephritis. Contribution of renal histologic data

TL;DR: Outcome predictions based on the strongest clinical predictors (age, sex, and serum creatinine level) were significantly enhanced by the addition of activity and chronicity indexes, and immunosuppressive agents appeared to provide a slight therapeutic advantage over oral corticosteroids alone.